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Autism spectrum disorder (ASD) is a neurodevelopmental disorder that affects 1 in 68 chil-
dren in the United States. Even though it is a common disorder, only two medications
(risperidone and aripiprazole) are approved by the U.S. Food and Drug Administration (FDA)
to treat symptoms associated with ASD. However, these medications are approved to treat
irritability, which is not a core symptom of ASD. A number of novel medications, which
have not been approved by the FDA to treat ASD have been used off-label in some studies
to treat ASD symptoms, including medications approved for Alzheimer’s disease. Inter-
estingly, some of these studies are high-quality, double-blind, placebo-controlled (DBPC)
studies. This article systematically reviews studies published through April, 2014, which
examined the use of Alzheimer’s medications in ASD, including donepezil (seven studies,
two were DBPC, five out of seven reported improvements), galantamine (four studies,
two were DBPC, all reported improvements), rivastigmine (one study reporting improve-
ments), tacrine (one study reporting improvements), and memantine (nine studies, one
was DBPC, eight reported improvements). An evidence-based scale was used to rank each
medication. Collectively, these studies reported improvements in expressive language and
communication, receptive language, social interaction, irritability, hyperactivity, attention,
eye contact, emotional lability, repetitive or self-stimulatory behaviors, motor planning,
disruptive behaviors, obsessive–compulsive symptoms, lethargy, overall ASD behaviors,
and increased REM sleep. Reported side effects are reviewed and include irritability, gas-
trointestinal problems, verbal or behavioral regression, headaches, irritability, rash, tremor,
sedation, vomiting, and speech problems. Both galantamine and memantine had sufficient
evidence ranking for improving both core and associated symptoms of ASD. Given the lack
of medications approved to treat ASD, further studies on novel medications, including
Alzheimer’s disease medications, are needed.
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BACKGROUND
Autism spectrum disorder (ASD) is a heterogenous neurodevel-
opmental disorder that is defined by behavioral observations and
characterized by developmental delays in communication and
social interaction and by repetitive behaviors and/or restricted
interests. The most recent prevalence of ASD in the United States
(U.S.) is now 1 in 68 children, including 1 in 42 boys (1). Only
two medications have been approved by the U.S. Food and Drug
Administration (FDA) for ASD and these medications, risperidone
and aripiprazole, are indicated to treat irritability, an associated
but not core symptom of ASD (2, 3). Since irritability is not a
core feature of ASD, there are currently no U.S. FDA approved
medications for treating the core symptoms of ASD.
A number of novel medications have been used to treat
the symptoms of ASD (4, 5). Some of these medications are
approved for the treatment of Alzheimer’s disease. A connection
between Alzheimer’s disease and autism has been proposed by
some investigators (6) and will be reviewed below. Because of
the evidence of this connection, several medications approved
for Alzheimer’s disease have been investigated for use in ASD.
To date, five medications have been approved by the U.S. FDA
for the treatment of Alzheimer’s disease: Tacrine (Cognex®,
1993), Donepezil (Aricept®, 1996), Rivastigmine (Exelon®, 2000),
Galantamine (Razadyne®, 2001), and Memantine (Namenda®,
2003). Donepezil, galantamine, rivastigmine, and tacrine are
cholinesterase inhibitors, and work by preventing the breakdown
of acetylcholine. Galantamine also stimulates nicotinic cholinergic
receptors and therefore can increase the release of acetylcholine
(7). Memantine is distinct from these other medications and
modulates glutamate neurotransmission.
Several lines of evidence have implicated abnormalities in the
cholinergic system in ASD (8). First, studies examining post-
mortem brain samples from individuals with ASD have reported
abnormalities in the cholinergic system (9–11). Early studies com-
pared the cholinergic system in frontal, parietal, hippocampus,
and cerebellar tissue from typically developing adults to similarly
aged autistic adults with intellectual disability. One of these stud-
ies found decreases in muscarinic M1 receptors in the parietal
cortex and nicotinic receptors in the frontal and parietal cor-
texes, with a decrease in α4 and β2 nicotinic subtypes confirmed
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by immunochemistry in the parietal cortex (9). Another study
found significant changes in nicotinic receptors but no significant
changes in muscarinic receptors or in the presynaptic cholinergic
enzyme choline acetyltransferase in the cerebellum. Consistent
nicotinic receptor changes included decreases in the α4 receptor
subtype in several types of cells including granule and Purkinje
cells, as well as increases in the α7 receptor subtype in the granule
cell layer (11). In contrast, using quantitative receptor autora-
diographic studies, no changes in cholinergic receptor binding
were found in the hippocampus (12). Later, a study comparing
typically developing and autistic adults showed a decrease in α7
and β2 but not α4 nicotinic acetylcholine receptor subunits in the
thalamus (10). Secondly, a positron emission tomography study
reported a decrease in acetylcholinesterase activity in the bilateral
fusiform gyri in ASD adults, as compared to typically develop-
ing adults, with this decrease correlated with objective scales of
individual participant social disability (13). Thirdly, functional
analysis of gene networks altered in individuals with ASD implicate
synaptic cholinergic receptor families of genes (14) and epige-
netic changes in both ASD and Rett syndrome have been linked
to decreased expression of the CHRNA7 gene encoding the nico-
tinic receptor subtypeα7 (15). Lastly, some studies have implicated
cholinergic abnormalities in an animal model of ASD. The BTBR
ASD mouse model demonstrates lower basal levels of extracel-
lular acetylcholine in the prefrontal cortex (16) and injection of
the acetylcholinesterase inhibitor donepezil into the BTBR mouse
(systemically or directly) in the dorsomedial striatum, the rodent
homolog of the caudate nucleus, ameliorated many core ASD
behaviors (17). Thus, there is substantial support for the idea that
treatments that modulate the cholinergic system might be helpful
in ASD (18).
Several lines of scientific evidence have also pointed to abnor-
malities in glutamate metabolism in individuals with ASD as
identified by imaging, genetic, and post-mortem studies. Proton
magnetic resonance spectroscopy has demonstrated abnormalities
in glutamate metabolism in individuals with ASD. For example,
the glutamate+ glutamine peak has been found to be increased
in individuals with ASD as compared to controls in the auditory
cortex (19), anterior cingulate cortex (20, 21), and basal ganglia
(22). Another study found that the glutamate/glutamine ratio in
the amygdala–hippocampal region was increased in ASD indi-
viduals as compared to controls (23), while one study found an
increase in glutamate/creatine in the putamen in individuals with
ASD (24). Interestingly, the magnetic resonance spectroscopy glu-
tamate+ glutamine peak in the basal ganglia of ASD individuals
was correlated with a measure of impairment in social communi-
cation (22) and the glutamate/creatine ratio in the putamen was
correlated with ASD symptoms (social interaction) (24). How-
ever, studies examining glutamate in frontal brain regions have
demonstrated inconsistent results. For example, as compared to
controls, individuals with ASD demonstrated a decrease in the
GABA/glutamate ratio in the frontal cortex in one study (25) while
the glutamate+ glutamine peak was not different between ASD
and control individuals in the prefrontal cortex in another study
(22). The glutamate/creatine ratio was decreased in ASD indi-
viduals in the frontal lobes, as compared to controls, in another
study (26).
Genetic studies have implicated abnormalities in ionotropic
glutamate receptors in ASD. Genetic studies have associated ASD
with abnormalities in subunits of N -methyl-d-aspartate (NMDA)
(27–30),α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA) (31), and kainate (32, 33) receptors and the mitochon-
drial aspartate/glutamate carrier (34–36). Genetic syndromes that
have a high prevalence of ASD features demonstrate abnormalities
in glutamate neurotransmission. For example, haploinsufficiency
of SHANK3, a gene that encodes postsynaptic scaffolding pro-
teins for glutamate receptors, is characteristic of many patients
with Phelan–McDermid syndrome, a genetic disorder with a high
prevalence of ASD (37). Interestingly, genetic animal models of
ASD have also demonstrated involvement of glutamate recep-
tors. For example, one of the main areas of research is the Fragile
X mouse model where abnormalities in metabotropic glutamate
receptor subtype 5 (mGluR5) have been linked to behavioral and
cognitive abnormalities that overlap symptoms associated with
ASD (38).
Lastly, post-mortem studies have also implicated glutamate
abnormalities. Cerebellum samples from individuals with ASD
have demonstrated an increase in mRNA for AMPA 1, 2, and 3
receptors and glutamate/aspartate transporter 1 and 2, an increase
in protein levels of glutamate/aspartate transporter 1 and 2 and
AMPA 1 and NMDA 1 receptors, but a decrease in AMPA recep-
tor density (39). In addition, other studies have demonstrated an
increase in mGluR5 protein in the vermis (40) and superior frontal
cortex (41) of children with ASD. One study reported decreased
levels of kidney-type glutaminase in the anterior cingulate cortex
of individuals with ASD (42), while another study demonstrated
an increase in the mitochondrial aspartate/glutamate carrier in
the prefrontal cortex but not in the cerebellum of individuals with
ASD (43). Thus, there is substantial evidence for glutamate abnor-
malities in individuals with ASD, suggesting the treatments that
modulate glutamate may be helpful in ASD.
Memantine is an NMDA receptor antagonist and regulates the
activity of glutamate, a neurotransmitter involved in memory
and learning. Normally glutamate attaches to NMDA receptors
allowing calcium to then enter freely into cells. Memantine pre-
vents this by partially blocking NMDA receptors. Memantine has
been reported to help obsessive–compulsive disorder (OCD) as
well as impulsive behaviors in open-label (44–48), single blind
(49), and placebo-controlled studies (50, 51). In animal mod-
els, memantine has also been shown to decrease evidence of
neuroinflammation (52).
Given this background, this article reviews studies that have
been published to date, which have reported on the use of these
Alzheimer’s medications in ASD individuals. Overall, this review
demonstrates that there is significant scientific support for some
of these medications in the treatment of core ASD symptoms, sug-
gesting that further clinical trials may be helpful to help define the
role for some of these medications for the treatment of individuals
with ASD.
METHODS
SEARCH STRATEGY
A computer-aided search of PUBMED [website (http://www.
ncbi.nlm.nih.gov/entrez)] and Google Scholar databases from
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Records identified through 
database searching 
(n = 490) 
Records excluded 
(n = 370) 
Reason:
370  Did not use Alzheimer’s medicine in ASD 
Records after 88 duplicates removed 
(n = 404) 
Additional records identified through 
other sources 
(n = 2) 
Records screened 
(n = 404) 
Studies included in qualitative synthesis (n = 21):
Donepezil: 7 studies† 
Galantamine: 4 studies† 
Rivastigmine: 1 study 
Tacrine: 1 study 
Memantine: 9 studies 
† Total studies = 22 as one study reported on the use of donepezil and galantamine 
Full-text articles excluded 
(n = 13) 
Reason:
13    Review articles/letters, no new data 
Full-text articles 
assessed for eligibility 
(n = 34) 
FIGURE 1 | Study flow chart.
inception through the end of April, 2014 was conducted to iden-
tify pertinent articles using the search terms “autism,” “autis-
tic,” “ASD,” “pervasive developmental disorder,” “PDD,” and
“Asperger” in all combinations with the terms: “donepezil,”“galan-
tamine,” “memantine,” “rivastigmine,” “tacrine,” “Alzheimer,”
“cholinesterase inhibitor,”and“NMDA antagonist.”The references
cited in identified articles were also searched to locate additional
studies (two studies total). Figure 1 depicts the studies identified
during the search process.
STUDY SELECTION
Studies were included if they: (1) involved individuals with ASD,
and (2) administered a medication approved for Alzheimer’s dis-
ease to at least one individual with ASD. Articles that did not
present new or unique data (such as review articles or letters to
the editor) and animal studies were excluded. Studies on Rett syn-
drome and Childhood Disintegrative Disorder were also excluded.
One reviewer screened titles and abstracts of all potentially rel-
evant studies. After screening all records, 34 publications were
identified and independently reviewed by both reviewers; 21 stud-
ies met inclusion criteria (see Figure 1). Within each section of
this review, strengths and limitations of studies are discussed and
recommendations for additional research are offered.
LEVEL OF EVIDENCE RATINGS
Although we considered conducting a meta-analysis on identified
treatments, the lack of standard outcomes and the limitations in
study design prevented a meta-analysis of any identified treatment.
Table 1 | Levels of evidence.
Level Description
1a SR or meta-analysis of RCTs with homogeneity or Cochrane
review with favorable findings
1b Prospective high-quality RCT
2a SR of cohort (prospective, non-randomized) studies with
homogeneity
2b Individual cohort (prospective, non-randomized) study or
low-quality RCT
3a SR of case–control (retrospective) studies with homogeneity
3b Individual case–control (retrospective) study
4 Case-series or reports
5 Expert opinion without critical appraisal or based on physiology or
bench research
RCT, randomized controlled trial; SR, systematic review.
Table 2 | Grade of recommendation.
Grade Description
A At least one level 1a study or two level 1b studies
B At least one level 1b, 2a, or 3a study, or two level 2b or 3b studies
C At least one level 2b or 3b study, or two level 4 studies
D Level 5 evidence, or troublingly inconsistent or inconclusive
studies of any level, or studies reporting no improvements
N No studies identified
As an alternative, we provide a grade of recommendation (GOR)
for each treatment based on the level of evidence (LOE). Using
a well-established scale (53), each study was individually assessed
to determine the LOE, ranging from level 1 to 5 (Table 1). After
assessing all identified studies for each treatment, a GOR ranging
from A (solid evidence) to D (limited, inconsistent, or inconclu-
sive evidence) was assigned (Table 2). Since a treatment could be a
GOR of D for several reasons, we specified if the treatment received
this rating because the evidence was a single case report or series
(SC), was only based on bench research (BR), demonstrated an
overall neutral effect (NE), or was found to be possibly detrimen-
tal (DE). If no studies were identified for a treatment, a GOR of
N (no studies) was assigned. The overall ratings of Alzheimer dis-
ease medications used for ASD are found in Table 3. Table 4 lists
the types of symptoms improved with each particular medication,
while Table 5 compiles the side effects by medication.
RESULTS
DONEPEZIL
Seven studies reported on the use of donepezil in individuals with
ASD, with five studies (71%) reporting improvements. Five stud-
ies were open-label or retrospective case-series. The first identified
study was an uncontrolled, retrospective, open-label study of eight
children (LOE 4) with autistic disorder (mean age 11.0± 4.1 years)
and reported improvements in irritability and hyperactivity with
donepezil (up to 10 mg/day) after at least 2 months of use; side
effects included mild irritability (one patient) and gastrointesti-
nal problems (nausea and vomiting in 1 patient) (54). Another
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uncontrolled, retrospective case-series (LOE 4) of eight children
with PDD (ages 10–17 years) used donepezil (2.5–30 mg/day;
mean 18 weeks of treatment) for ADHD-type symptoms and
reported improvements in ADHD symptoms, communication,
Table 3 | Overall ratings of Alzheimer disease medications used for
autism spectrum disorder.
Medication Uncontrolled
studies positive
(positive/total)
Controlled
studies positive
(positive/total)
Grade of
recommendation
Donepezil 80% (4/5) 50% (1/2) D – NE
Galantamine 100% (2/2) 100% (2/2) B
Rivastigmine 100% (1/1) D – SC
Tacrine 100% (1/1) D – SC
Memantine 88% (7/8) 100% (1/1) B
and socialization; one patient had to stop the medication due to
side effects (tremor, irritability, and distractibility) (55). An uncon-
trolled, open-label study (LOE 4) of five children with ASD (ages
2.5–6.9 years) with deficits in REM sleep administered donepezil,
which increased the percentage of REM sleep as measured by
polysomnography after 1 month of treatment (56). In a case report
(LOE 4) of a 5-year-old child with ASD, treatment with donepezil
(5 mg at bedtime) over 6 weeks led to significant improvements in
communication, eye contact, and hyperactivity (57). Finally, one
case report (LOE 4) of three adults with autism treated with galan-
tamine reported that the use of donepezil (dose not reported) led
to verbal and behavioral regression in one adult (58).
Two studies were double-blind, placebo-controlled (DBPC)
studies. The first DBPC study contained 43 children (LOE 1b)
with autism (mean age 6.8 years) and administered donepezil or
placebo over 6 weeks and reported improvements in expressive
and receptive speech and a decrease in overall autistic behaviors in
the treatment group; side effects included diarrhea and stomach
Table 4 | Improvements reported in studies of Alzheimer disease medications in ASD.
Symptom Donepezil Galantamine Rivastigmine Tacrine Memantine
Expressive language X X X X X
Receptive language X X
Social interaction X X X
Irritability X X X X
Hyperactivity X X X X
Attention X X X
Eye contact X X X X
Emotional lability X
Repetitive or self-stimulatory behaviors X
Motor planning X
Disruptive behaviors X
Obsessive–compulsive behaviors X
Lethargy X
Overall ASD symptoms X X
Increased REM sleep X
Table 5 | Reported side effects of Alzheimer disease medications in ASD.
Side effect Donepezil Galantamine Rivastigmine Tacrine Memantine
Irritability X X
Gastrointestinal problems X X
Verbal or behavioral regression X X
Headaches X
Worsened behaviors X
Irritability X
Rash X
Excessive sedation X
Vomiting X
Speech problems X
Tremor X
Distractibility X
Increased seizures X
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cramps (59). In the second DBPC study of 34 children (LOE 1b)
with ASD (age range 8–17 years), donepezil (dose 5–10 mg/day),
or placebo was administered over 10 weeks, with a 10-week open-
label trial of the medication for children in the placebo group
who did not respond. No significant improvements were found in
the donepezil group compared to the placebo group; no serious
adverse events were observed (60).
Overall, the evidence for donepezil is inconsistent for improve-
ments in ASD symptoms as one of the two DBPC studies was
negative and one of the five case-series reported detrimental effects
rather than beneficial effects of donepezil. As two case-series
reported improvements in ADHD symptoms and one case-series
demonstrated improvements in REM sleep, donepezil may have
favorable effects on subsets of children with ASD who have these
specific symptoms. Clearly, several studies have demonstrated
favorable effects of donepezil, suggesting that further studies
focused on specific symptoms may be warranted in the future.
GALANTAMINE
Four studies reported on the use of galantamine in individuals
with ASD, with all four studies reporting improvements. Two of
the studies were uncontrolled, open-label, or case-series (LOE 4).
In the first case-series (LOE 4) of three adults with autism (21 to
42 years old), galantamine 4–16 mg/day was reported to increase
expressive language and communication; however; one individ-
ual had a regression when put on donepezil (58). The second
study was a 12-week, uncontrolled, open-label study (LOE 4) of
galantamine in 13 children with autism (mean age 8.8± 3.5 years),
which reported improvements in parent-rated social withdrawal
and irritability on the Aberrant Behavior Checklist (ABC) and
improvements in attention and emotional lability on the Con-
ner’s Parent Rating Scale – Revised; eight patients were rated as
improved on the Clinical Global Impression Scale (CGI); no sig-
nificant adverse effect were found except for headaches in one
child (61).
Two studies were DBPC. The first DBPC study of 20 children
(LOE 2b) with autism (mean age 7.4± 3.2 years) reported a signif-
icant improvement with galantamine (dose not noted) compared
to placebo on the ABC in irritability, eye contact, hyperactivity, and
inappropriate speech; side effects were minimal (62). The second
DBPC study of 40 children (LOE 1b) with autism (ages 4–12 years)
reported that galantamine (up to 24 mg/day) for 10 weeks led to
significant improvements in lethargy/social withdrawal and irri-
tability on the ABC compared to placebo; side effects were similar
in both groups (18).
Given that galantamine has been shown to improve both core
and associated ASD symptoms in both open-label and DBPC stud-
ies (one high-quality and one of lower quality), it is given a GOR
of B. Given this preliminary positive evidence, it is clear that large
multicenter high-quality controlled trials should be conducted to
provide efficacy data to further define the role of galantamine in
the treatment of ASD.
RIVASTIGMINE
An open-label study of 32 children (LOE 4) with autism used
rivastigmine (0.4–0.8 mg twice a day) for 12 weeks and reported
improvements in expressive speech and overall autism symptoms
(63). Given the limited number of studies on rivastigmine for
the treatment of ASD, this treatment is given a GOR of D – SC.
Because of the positive preliminary results and the fact that it was
well tolerated, further larger open-label or blinded studies may be
warranted for this treatment in ASD.
TACRINE
An open-label study of three individuals (LOE 4) with ASD (mean
age 17.4± 33.2 years) administered 20 mg of tacrine daily and
reported mild improvements in irritability, hyperactivity, eye con-
tact, and inappropriate speech as rated by combined parent and
teacher scales (ABC); no significant side effects were reported (64).
Given the limited number of studies on tacrine for the treatment
of ASD, this treatment is given a GOR of D – SC. Because of the
positive preliminary results and the fact that it was well tolerated,
further studies may be warranted for this treatment in ASD to see
if a wider number of children with ASD respond to this treatment.
MEMANTINE
Nine studies reported on the use of memantine in individuals with
ASD, with eight studies (89%) reporting improvements. Eight
studies were open-label or retrospective case-series. In the first
study, Chez et al. (63) administered open-label (LOE 4) meman-
tine (mean dose 8.1 mg/day, range 2.5–10 mg/day) in 30 children
(mean age 8.92 years) with ASD and reported that for those treated
more than 8 weeks (mean duration 18 weeks, range 8–40 weeks),
16 (53%) demonstrated significant improvements and 10 (33%)
showed more mild improvements in attention, eye contact, lan-
guage (expressive and receptive), repetitive behaviors, and motor
planning; no significant side effects were observed (65). One case
report (LOE 4) described the effects of memantine on a 23-year-
old man with autistic disorder and observed improvements in
disruptive behavior with memantine 10 mg/day over an 8-month
period (66). An uncontrolled, open-label (LOE 4) study of 151
individuals with ASD (ages 2.58–26.33 years old) used memantine
at a dose ranging from 2.5 to 30 mg and reported improvements
in language, self-stimulatory behaviors, and social behavior; 22
patients (15%) had worsened behavior as a side effect (67).
An uncontrolled, open-label, and retrospective study (LOE 4)
examined the effects of memantine (maximum dose 20 mg/day;
duration of use 1.5–56 weeks) in 18 children with ASD (age 6–
19 years) and reported improvements in social withdrawal and
inattention; 7 patients (39%) had side effects including irritability
(4 patients), rash (1 patient), excessive sedation and vomiting (1
patient), and an increase in seizures (1 patient); 4 patients had to
discontinue memantine (68). An uncontrolled, open-label (LOE
4) study of four patients with ASD (mean age 17.4± 33.2 years)
administered memantine 20 mg daily for 4 weeks and reported
significant improvements on combined parent and teacher ratings
on the ABC in irritability, hyperactivity, and inappropriate speech
(p< 0.05 for all three); no side effects were reported (69). An
uncontrolled, open-label study (LOE 4) used memantine (start-
ing at 5 mg, increasing every 2 weeks up to 20 mg/day; mean
final dose 18.3± 2.6 mg/day; mean use 34.7± 36.5 weeks, range
8–104 weeks) in six individuals with Fragile X and concomitant
PDD (mean age 18.3± 3.8 years, range 13–22 years; four had autis-
tic disorder and two had PDD). Four of the six patients were rated
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as “much improved” or “very much improved” on the CGI; non-
significant improvements were observed on the ABC and SRS; two
individuals experienced irritability, which led to drug discontinua-
tion (70). A case report (LOE 4) of a 15-year-old boy with Asperger
disorder, OCD, and Tourette disorder described the use of meman-
tine (2.5 mg increasing to 10 mg/day) to treat the OCD symptoms
and observed a significant reduction in OCD symptoms, includ-
ing rituals and intrusive thoughts as well as improvements in social
interaction; no significant adverse events were observed (71). One
case study (LOE 4) reported stuttering and speech loss in two
children with ASD who were taking memantine; in one child the
speech improved with stopping the medication, while in the other
child it improved while continuing the medication (72).
Only one study was DBPC and was a 10-week study of 40
children (LOE 1b) with ASD (ages 4–2 years). This study adminis-
tered memantine (up to 15 mg/day if 10–40 kg; 20 mg/day if over
40 kg) compared to placebo and reported significant improve-
ments on the ABC in irritability (p< 0.001), stereotypy (p< 0.01),
and hyperactivity/non-compliance (p< 0.01); side effects were
similar in both groups (73).
Given that the majority of clinical studies, including a DPBC
study, provide positive evidence of improvements in both core and
associated ASD symptoms, a GOR of B is provided for memantine
for the treatment of ASD. Several studies have outlined adverse
effects in certain patients with memantine treatment. Interest-
ingly, memantine has been reported to both improve and worsen
irritability. This suggests that there might be specific subgroups of
children with ASD that respond optimally to memantine. Clearly
larger, well-designed, and blinded studies are needed to further
evaluate the efficacy of memantine in children with ASD as well
as define the subgroups that might optimally respond to this
medication.
DISCUSSION
This manuscript reviews the evidence for the use of medications
which are FDA approved for Alzheimer’s disease in individuals
with ASD. These medications target two neurotransmitter sys-
tems, acetylcholine and glutamate, which are both neurotrans-
mitter systems with abnormalities associated with ASD. Overall
five medications, four which target acetylcholine neurotransmis-
sion and one that targets glutamate neurotransmission, which are
FDA indicated for Alzheimer’s disease have been used in individ-
uals with ASD. To provide recommendations on the evidence for
the potential usefulness of these medications for the treatment
of ASD, we used an objective scale to rate the evidence for the
utility of these medications for treating core and associated symp-
toms of ASD. Overall, we found that one medication that targets
acetylcholine neurotransmission, galantamine, and one medica-
tion that targets glutamate neurotransmission, memantine, have
reasonable evidence for the treatment of core and associated symp-
toms of ASD, although both require larger controlled studies to
provide further efficacy data and define subgroups of individuals
with ASD who may best respond to these treatments with limited
adverse effects. Two medications, rivastigmine and tacrine, both of
which target the acetylcholine neurotransmitter system, have only
preliminary uncontrolled studies to support their use, so further
studies need to be performed before recommendations can be
made. One medication that targets acetylcholine, donepezil, has
several studies investigating its use in individuals with ASD but
the results of some of the studies, particularly the DBPC studies,
are inconsistent, making recommendations difficult at this time,
although in certain subgroups (ADHD symptoms or REM sleep
problems) it might be of use.
Given the fact that there is no FDA approved medication for
the core symptoms of ASD and considering the limited proven
effective treatments for ASD, studies are needed to identify novel
treatments. Because several of the medications reviewed here show
promising evidence for effectiveness for treating core and associ-
ated ASD symptoms, such medications should undergo further
study in clinical trials to confirm their effectiveness for treating
individuals with ASD.
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